Health and science are at the heart of everything we do
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products.
We have an extensive research network, which allows us to work closely with the global scientific community to advance the understanding of probiotics and the human microbiome. Around 10 percent of our net sales is invested in research and development to expand our product portfolio further, discover new bacteria strains and deepen the knowledge of probiotics.
Our products contain strains of the lactic acid bacterium L. reuteri (Limosilactobacillus reuteri, formerly known as Lactobacillus reuteri). L. reuteri has co-evolved with humans and, as a result, has a strong adaptation and naturally colonizes and interacts with the human body. Our probiotic strains have been published in more than 250 articles in scientific journals, proving their effectiveness and safety.
At BioGaia, we operate as a lean organisation and have parts of our value chain externally. This efficiency and diversification of our production chain allow us to adapt to market needs in a more flexible way. We have two types of distribution: through distribution partners and our own distribution. Our products are sold in more than 100 countries worldwide through its partnerships with nutrition and pharmaceutical companies, while our own distribution extends to five markets.Contact us
BioGaia’s class B shares are listed on the Mid-cap segment of the Nasdaq OMX Nordic Stockholm exchange. Read more
Our business model
The BioGaia business model is built on three external networks - research, production, and distribution. As a result of this business model, we have been able to grow globally and operate as a lean, efficient, and agile company. Read more
BioGaia’s probiotic products are sold through approximately 80 distribution partners in 100 countries around the world.
The history of BioGaia dates back to the 1980s, a time when HIV/AIDS was first discovered. Two scientists, Sven Lindgren and Walt Dobrogosz, examined different probiotics with the aim of finding out what effect they had on the virus. Read more
To date, 224 clinical studies using BioGaia’s human strains of L. reuteri have been performed on 18,000 individuals of all ages. (May 2020)
We have a strategy with a long-term approach and clear goals, structure and priorities for our sustainability initiatives.